Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07836396
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PF-07836396 is an experimental self-amplifying ribonucleic acid (saRNA) vaccine candidate developed by Pfizer for the prevention of influenza. As an saRNA vaccine, it contains the genetic information for influenza virus antigens along with the enzymatic machinery required for RNA replication within the host cell. This self-amplification process is designed to enhance the magnitude and duration of antigen expression compared to conventional mRNA vaccines, potentially allowing for lower dosing levels while maintaining high immunogenicity. PF-07836396 is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and ability to induce protective immune responses in healthy adults.
- Other names
- PF-07836396 Influenza saRNAPF07836396 Influenza saRNAPF 07836396 Influenza saRNA
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on PF-07836396.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07836396.